中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
US Oncology Research
合作者
Eli Lilly and Company
Sanofi

关键词

抽象

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

描述

This is a Phase II, open- label, randomized, noncomparative study. Patients will be stratified at randomization by ECOG PS. There is no intent to have equal numbers of patients for each PS (ie, 0, 1, and 2), but rather stratification will be conducted to ensure that the 2 treatment arms are well-balanced for ECOG PS.

Patients will be randomly assigned to either Arm 1 - Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours or Arm 2 - Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes. Taxotere and Eloxatin will be given on Day 1 of each 21-day cycle; ERBITUX is given on Days 1, 8, and 15 of each cycle.

Treatment will continue until disease progression or intolerable toxicity. Patients who achieve a CR will receive an additional 2 cycles of treatment. Patients will be limited to 24 months of participation, counted from the date of the first dose of study drug.

日期

最后验证: 09/30/2016
首次提交: 08/14/2007
提交的预估入学人数: 08/15/2007
首次发布: 08/16/2007
上次提交的更新: 10/13/2016
最近更新发布: 11/27/2016
首次提交结果的日期: 01/11/2016
首次提交质量检查结果的日期: 01/11/2016
首次发布结果的日期: 02/10/2016
实际学习开始日期: 06/30/2007
预计主要完成日期: 03/31/2012
预计完成日期: 03/31/2012

状况或疾病

Gastric Cancer Adenocarcinoma Metastatic

干预/治疗

Drug: Docetaxel

Drug: 2- Docetaxel plus oxaliplatin plus cetuximab

Drug: oxaliplatin

相 2

手臂组

干预/治疗
Active Comparator: 1- Docetaxel plus Oxaliplatin
Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
Active Comparator: 2- Docetaxel plus oxaliplatin plus cetuximab
Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Drug: 2- Docetaxel plus oxaliplatin plus cetuximab
ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- Patient has histologically confirmed Stage IV adenocarcinoma of the GEJ/stomach

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

- Patients must have measurable disease

- Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2

- Patient is greater than 18 years of age

- If present, any pre-existing (current) peripheral neuropathy must be ≤ Grade 1

- Patient's laboratory values must fall within the limits set forth in section 4.2 of the protocol

- Patient has a negative serum pregnancy test within 7 days prior to registration (female patients of childbearing potential)

- If fertile, patient (male or female) has agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a 2 month period thereafter

- Patient (or guardian) has signed a Patient Informed Consent Form

- Patient (or guardian) has signed a Patient Authorization Form

Exclusion Criteria:

- Patient has any metastatic disease other than that defined in section 4.2 (criterion #1)

- Patient has had prior treatment that included anything other than adjuvant radiation plus treatment with 5-FU and leucovorin. Prior treatment must have been completed > 6 months prior to registration in current study. No other prior regimens are allowed.

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

- If present, any peripheral neuropathy is > Grade 1

- Patient has a known hypersensitivity to Taxotere (or any drug formulated with Polysorbate-80), or Eloxatin

- Has had a prior severe infusion reaction (Grade 4) to a monoclonal antibody

- Has received prior therapy, at any time, which specifically and directly targets the EGFR pathway

- Patient is receiving concurrent immunotherapy or any other concurrent treatment for their cancer

- Has had prior stem cell or bone marrow transplant or any organ transplant with the exception of corneal transplant or cadaver bone graft

- Has a significant history of uncontrolled cardiac disease; ie, uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, or cardiomyopathy with decreased ejection fraction (LVEF<50%)

- Has evidence of CNS involvement (CNS imaging is not required for study enrollment unless clinically suspected CNS disease is present.)

- Patient has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection

- Patient is known to be HIV positive or have a history of hepatitis B or C

- Patient has a history of other malignancy within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix , or superficial transitional cell carcinoma of the bladder), which could affect the diagnosis or assessment of current condition.

- Patient is a pregnant or lactating woman

结果

主要结果指标

1. Progression-free Survival [Treatment will continue until disease progression or intolerable toxicity, up to 2 years]

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

次要成果指标

1. Overall Survival [Treatment will continue until disease progression or intolerable toxicity]

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

2. Objective Response Rate (ORR) [Treatment will continue until disease progression or intolerable toxicity.]

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

3. Time to Response [Treatment will continue until disease progression or intolerable toxicity]

For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

4. Duration of Response [Treatment will continue until disease progression or intolerable toxicity]

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge